HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?

An analysis comparing Hologic (HOLX) and Quest Diagnostics (DGX) in the women's health market, projected to grow at a 9.25% CAGR through 2030, suggests both companies offer unique investment opportunities. Hologic, despite facing macroeconomic headwinds and a recent 31.6% share price decline, benefits from its diversified revenue model and a P/S ratio below the industry average, while Quest Diagnostics is experiencing strong growth in Women's and Reproductive Health, supported by recent acquisitions and upward EPS estimate revisions, with analysts more bullish on DGX.

Analysis

The women's health diagnostics market is poised for significant expansion, projected by Research and Markets to grow at a 9.25% compound annual growth rate through 2030, driven by technological advancements and increased healthcare spending. Within this attractive sector, Hologic (HOLX) and Quest Diagnostics (DGX) present distinct profiles. Hologic, with a $12.10 billion market cap, is a pure-play women's health company leveraging durable growth drivers like its Aptima and Panther Fusion assays, with its BV/CV/TV assay showing strong double-digit growth. Its Breast Health recurring service revenues grew 12% year-over-year in Q2, and the Endomagnetics acquisition is set to enhance its Interventional Breast portfolio. However, HOLX faces headwinds including weaker HIV testing in Africa, impacts from international events like South Korea's physician strike and reduced China hospital spending affecting Q2 cytology and perinatal sales, a 7.4% decline in capital equipment sales revenue, and macroeconomic pressures such as tariffs expected to cost $20-25 million per quarter. Despite these challenges and a 31.6% share price decline in the past six months, Hologic maintains sound financial health and its fiscal 2025 sales and EPS are estimated to improve by 1.2% and 3.2% respectively, though bottom-line estimates show mixed recent movements. Its forward P/S multiple of 2.87X is above Quest's but below its industry average.

Quest Diagnostics, a larger entity with a $19.12 billion market cap, is experiencing robust growth in its Women's and Reproductive Health segment, bolstered by prenatal and hereditary genetic testing, and a new HPV self-collection solution. The company reported a 12% year-over-year revenue increase in Q1 2025 across its broader clinical areas, with an 8.3% growth in adjusted EPS, supported by eight acquisitions in 2024 and new health plan relationships, including becoming the first independent lab in the Optum Health preferred network. Quest is also advancing operationally through automation, AI, and a partnership with Google Cloud. Analysts appear more bullish on DGX, with upward EPS estimate revisions for 2025, projecting 9.2% sales growth and 8.6% EPS growth. Its shares have gained 4.9% in the past six months, contrasting with HOLX's decline. Quest's P/S multiple is 1.75X, below its industry average. However, a key concern for DGX is its escalating debt, which stood at $5.86 billion in long-term debt against $188 million in cash at the end of Q1. Both companies carry a Zacks Rank #3 (Hold), with the article suggesting a hold strategy for both, citing Hologic's long-term stability potential and Quest's promising growth and favorable recent performance.

Key Decisions for Investors

• Investors should acknowledge the strong secular growth trend in the women's health diagnostics market, projected at a 9.25% CAGR through 2030, as a positive backdrop for companies in this space.
• For Hologic (HOLX), consider its pure-play exposure and below-industry valuation against significant recent share price underperformance (-31.6%) and specific operational headwinds such as tariffs and softer capital equipment sales; the stock may appeal to long-term investors anticipating a turnaround once near-term pressures subside.
• For Quest Diagnostics (DGX), evaluate its strong top-line growth (12% YoY in Q1 2025), positive analyst sentiment, and strategic M&A activity, but remain vigilant regarding its substantial long-term debt of $5.86 billion relative to cash reserves.
• Given both HOLX and DGX hold a Zacks Rank #3 (Hold) and the article's neutral stance, investors might consider maintaining current positions while closely monitoring Hologic's ability to navigate its challenges and Quest's debt management alongside its growth execution before making new capital allocation decisions.